$XFOR
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and WaldenstrΓΆm macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Adam R. Craig
CEO
143
Employees
$2.75
Current Price
$51.34M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 1 | 1 | $11,883.64 | 4,600 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 1 | 1 | $11,883.64 | 4,600 | 1:2.83 |
| Sells | 1 | 1 | $33,658.33 | 11,767 | ||
| 2 months | Buys | 1 | 1 | $11,883.64 | 4,600 | 1:2.83 |
| Sells | 1 | 1 | $33,658.33 | 11,767 | ||
| 3 months | Buys | 1 | 1 | $11,883.64 | 4,600 | 1:29.76 |
| Sells | 3 | 3 | $353,715.66 | 83,779 | ||
See activity going back 12 months β create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Oct 16, 2026 | Craig Adam R Director | Purchase | 4,600 | $2.58 | $11,883.64 | View Details |
| Oct 1, 2026 | KIRSKE DAVID Chief Financial Officer | Sale | 11,767 | $2.86 | $33,658.33 | View Details |
| Aug 12, 2026 | Volpone John President | Sale | 24,576 | $4.44 | $109,228.03 | View Details |
| Aug 12, 2026 | Craig Adam R Director | Sale | 47,436 | $4.44 | $210,829.30 | View Details |
2 more transactions available β create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated-$0.18
ActualN/A
Revenue
Estimated$2.30M
ActualN/A
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.